|
|
Volumn 296, Issue 8, 2006, Pages 920-922
|
|
Report criticizes lack of FDA oversight
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
ROFECOXIB;
BUDGET;
COMMUNITY CARE;
DEFIBRILLATOR;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG MANUFACTURE;
ECONOMIC ASPECT;
FOOD AND DRUG ADMINISTRATION;
GOVERNMENT;
HEALTH HAZARD;
HEALTH SERVICE;
LEGAL ASPECT;
MEDICAL DECISION MAKING;
MEDICAL PRACTICE;
MEDICAL STAFF;
PATIENT COMPLIANCE;
POLITICS;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
PUBLIC HEALTH;
SEIZURE;
SHORT SURVEY;
ARTICLE;
ORGANIZATION AND MANAGEMENT;
UNITED STATES;
POLITICS;
PRODUCT SURVEILLANCE, POSTMARKETING;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 33747605115
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.296.8.920 Document Type: Short Survey |
|
Times cited : (7)
|
|
References (0)
|